A Phase 1, Single-Center, Five-Period, Single and Multiple Dose, Double-Blind, Placebo-Controlled First-in-Man Study to Assess the Safety and Pharmacokinetics of ZYN001 Administered as a Transdermal Patch to Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs ZYN 001 (Primary)
- Indications Fibromyalgia; Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Zynerba Pharmaceuticals
- 26 Jun 2017 Status changed from planning to recruiting, according to a Zynerba Pharmaceuticals media release.
- 17 Oct 2016 This trial is expected to begin in the first half of 2017, according to a Zynerba Pharmaceuticals media release.
- 11 Aug 2016 Zynerba expects to initiate Phase 1 studies in the second half of 2016.